Emad S Farag1, Harry V Vinters, Jeff Bronstein. 1. Movement Disorders Program, UCLA Department of Neurology, 300 UCLA Medical Plaza Ste. B200, Los Angeles, CA 90095, USA. efarag@mednet.ucla.edu
Abstract
BACKGROUND: Attempts at cell-based dopamine replacement therapy in Parkinson disease (PD) have included surgical implantation of adrenal medullary, fetal mesencephalic, and cultured human mesencephalic tissue grafts. Trials involving putamenal implantation of human retinal pigment epithelial (RPE) cells in PD have also been performed. Neuropathologic findings in humans undergoing RPE cell implantation have not heretofore been reported. We describe the brain autopsy findings from a subject enrolled in a clinical trial of RPE cells in gelatin microcarriers for treatment of PD, and suggest factors which may have impacted cell survival. METHODS: A 68-year-old man underwent bilateral surgical implantation of 325,000 RPE cells in gelatin microcarriers (Spheramine) but died 6 months after surgery. The left cerebral hemisphere was examined. Routine postmortem formalin fixation was performed and standard, as well as immunohistochemical methods used to highlight senile plaque and Lewy body pathologic changes, iron deposition, cellular inflammation, and reactive astrocytosis in implant regions. Manual cell counts were done of RPE cells. RESULTS: Hematoxylin-eosin and alpha-synuclein immunostains confirmed the diagnosis of PD. Needle tracts with matrix material and RPE cells were observed in the context of local inflammatory and astrocytic reactive change. A total of 118 cells were counted (estimated 0.036% survival). CONCLUSIONS: Retinal pigment epithelial cells are seen in human brain 6 months postimplantation, but overall survival of implanted cells appeared poor.
BACKGROUND: Attempts at cell-based dopamine replacement therapy in Parkinson disease (PD) have included surgical implantation of adrenal medullary, fetal mesencephalic, and cultured humanmesencephalic tissue grafts. Trials involving putamenal implantation of humanretinal pigment epithelial (RPE) cells in PD have also been performed. Neuropathologic findings in humans undergoing RPE cell implantation have not heretofore been reported. We describe the brain autopsy findings from a subject enrolled in a clinical trial of RPE cells in gelatin microcarriers for treatment of PD, and suggest factors which may have impacted cell survival. METHODS: A 68-year-old man underwent bilateral surgical implantation of 325,000 RPE cells in gelatin microcarriers (Spheramine) but died 6 months after surgery. The left cerebral hemisphere was examined. Routine postmortem formalin fixation was performed and standard, as well as immunohistochemical methods used to highlight senile plaque and Lewy body pathologic changes, iron deposition, cellular inflammation, and reactive astrocytosis in implant regions. Manual cell counts were done of RPE cells. RESULTS:Hematoxylin-eosin and alpha-synuclein immunostains confirmed the diagnosis of PD. Needle tracts with matrix material and RPE cells were observed in the context of local inflammatory and astrocytic reactive change. A total of 118 cells were counted (estimated 0.036% survival). CONCLUSIONS:Retinal pigment epithelial cells are seen in human brain 6 months postimplantation, but overall survival of implanted cells appeared poor.
Authors: Roy A E Bakay; Cathy D Raiser; Natividad P Stover; Thyagarajan Subramanian; Michael L Cornfeldt; Alfred W Schweikert; Richard C Allen; Ray Watts Journal: Front Biosci Date: 2004-01-01
Authors: C W Olanow; W Koller; C G Goetz; G T Stebbins; D W Cahill; L L Gauger; R Morantz; R D Penn; C M Tanner; H L Klawans Journal: Arch Neurol Date: 1990-12
Authors: R L Watts; C D Raiser; N P Stover; M L Cornfeldt; A W Schweikert; R C Allen; T Subramanian; D Doudet; C R Honey; R A E Bakay Journal: J Neural Transm Suppl Date: 2003
Authors: C R Freed; P E Greene; R E Breeze; W Y Tsai; W DuMouchel; R Kao; S Dillon; H Winfield; S Culver; J Q Trojanowski; D Eidelberg; S Fahn Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245
Authors: C Warren Olanow; Christopher G Goetz; Jeffrey H Kordower; A Jon Stoessl; Vesna Sossi; Mitchell F Brin; Kathleen M Shannon; G Michael Nauert; Daniel P Perl; James Godbold; Thomas B Freeman Journal: Ann Neurol Date: 2003-09 Impact factor: 10.422
Authors: Amanda L Piquet; Kala Venkiteswaran; Neena I Marupudi; Matthew Berk; Thyagarajan Subramanian Journal: Brain Res Bull Date: 2012-04-11 Impact factor: 4.077
Authors: Kala Venkiteswaran; Danielle N Alexander; Matthew D Puhl; Anand Rao; Amanda L Piquet; Jennifer E Nyland; Megha P Subramanian; Puja Iyer; Matthew M Boisvert; Erin Handly; Thyagarajan Subramanian; Patricia Sue Grigson Journal: Brain Res Bull Date: 2015-11-10 Impact factor: 4.077
Authors: Torsten Falk; Nicole R Congrove; Shiling Zhang; Alexander D McCourt; Scott J Sherman; Brian S McKay Journal: J Biomed Biotechnol Date: 2012-04-02